SEC Form 4 · accession 0001250853-18-000038
IOVANCE BIOTHERAPEUTICS, INC. · IOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maria Fardis
Officer — President and CEO · Director
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 8:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001425205
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.80 | Feb 9, 2018 | A | 500,000 | A | — | Feb 8, 2028 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Provided the Reporting Person is employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of 166,672 shares shall vest on February 9, 2019; and (ii) the remaining stock options shall vest as to 41,666 shares in eight quarterly installments over the two years following February 9, 2019.